Print

Attendee Registration - 6:00 am to 5:45 pm
EXHIBITIONS OPEN 9:30 AM to 2:00 PM

Main Plenary Session - Veterans Auditorium

Saturday, September 14, 2019 - There are Three parallel Sessions.  choose a tab Above

     
 

Educational Sessions

Faculty

Scheduled Time

Room 200 CD38 Monoclonal Antibody Therapy in MM: Mechanistic Insights and Resistance T Plesner/M Gatt 7:00 AM
Room 202 Genomic Predispositions to MGUS/MM S Kristinsson 7:00 AM
Room 203 Genomic Landscape of MM
R Fonseca/B Walker 7:00 AM
Room 204 Cell Free DNA Assays for MM Diagnosis and Evolution S Manier/J Lohr 7:00 AM
Room 206 Functional Genomic Studies of MM C Mitsiades/R Carrasco 7:00 AM
Room 210 Molecular Driven Treatment Approach to MM F Davies/J Keats 7:00 AM
Room 309 MRD Assessment in MM R Owen/S Oliva 7:00 AM
Room 310 Prevention and Management of Drug Related Toxicities in MM H Ludwig/R Vij 7:00 AM
Room 311 Novel targets and agents for MM E Ocio/L Boise 7:00 AM
Room 312 Imaging Techniques and Applications in MM E Zamagni/J Hillengass 7:00 AM
Room 313 New Concepts in Bone Disease Control for MM D Roodman/E Terpos 7:00 AM
     

CELLULAR IMMUNE THERAPIES FOR MULTIPLE MYELOMA - Veterans Auitorium

 Faculty

 
Session Chairs F Davies/E Stadtmauer  
Overview of Car T Cell Approaches to MM  A Cohen 8:15 AM
Cytokine Release Syndrome  N Shah 8:30 AM
Optimizing Car T cell therapy in MM  E Smith 8:45 AM
Mechanisms underlying non-response and resistance to Car T cells  N Raje 9:00 AM
Maintaining Car T Cell Response  N van de Donk 9:15 AM
Panel Discussions   9:30 - 9:50 AM
 This activity is supported by an unrestricted educational grant from Celgene Inc.    
     

Main Plenary Session - Veterans Auditorium

Faculty

 
     
Treatment of Previously Treated Myeloma    
Session Chairs S Kumar/M Boccadoro  
AB344: A Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma  S Kumar 10:00 AM
AB158: Safety and efficacy of once-weekly carfilzomib (K) dosing in frail patients (pts): a subgroup analysis from the phase 3 A.R.R.O.W. study  M Mateos 10:15 AM
AB418: Pomalidomide + Bortezomib + Dexamethasone After One Prior Line of Therapy in Bortezomib-Pretreated Multiple Myeloma: Subanalysis of OPTIMISMM  M Dimopoulos 10:30 AM
AB530: Efficacy of isatuximab/pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA-MM high-risk cytogenetics subgroup analysis  S Harrison 10:45 AM
AB368: Efficacy and Safety of Carfilzomib-Pomalidomide-Dexamethasone in Relapsed and/or Refractory Multiple Myeloma: Pooled Analysis of 2 Single Arm Studies  A Jakubowiak 11:00 AM
     
Myeloma Transplant and Maintenance Strategies    
Session Chairs M Alsina/M Minnema  
AB285: Profound MRD negativity rates after frontline tandem autologous-allogeneic stem cell transplantation followed by bortezomib maintenance in high-risk or young myeloma patients  R LeBlanc 11:15 AM
AB540: Maintenance therapy with either Lenalidomide or Bortezomib equally improves PFS and OS in High Risk Myeloma initially treated with Autotransplant.  H Alahwal 11:30 AM
AB163: Comparison of bortezomib versus lenalidomide maintenance therapy in newly-diagnosed, transplant-eligible multiple myeloma: results from the phase III GMMG-HD4 and -MM5 trials  E Mai 11:45 AM
AB692: Maintenance with Weekly Carfilzomib in Elderly newly Diagnosed Multiple Myeloma (IFM 2012-03).  A Bobin 12:00 PM
AB496: Measuring serological response to vaccination before and after autologous hematopoietic cell transplantation in multiple myeloma  A Merz 12:15 PM
     

PoSter Session II, Lunch and EXhibiTIONS 12:30 -2:00 PM

 

Main Plenary Session - Veterans Auditorium

     
Amyloidosis and Light Chain Deposition Disease    
Session Chairs G Merlini/M Gertz  
Treatment Approach of Amyloidosis  M Gertz  2:00 PM
Role of SCT in LC Amyloid Management  V Sanchorawala  2:15 PM
Novel treatment options for LC Amyloid  R Comenzo  2:30 PM
Management of LCDD  A Dispenzieri  2:45 PM
     
Waldenstrom's Macroglobulinemia    
Session Chairs I Ghobrial/R Garcia-Sanz  
Precursor Conditions  R Kyle 3:00 PM
Genomic Basis  Z Hunter  3:15 PM
Frontline Approaches to Treatment  E Kastritis  3:30 PM
Treatment of Relapsed/Refractory Disease  J Castillo  3:45 PM
Bing Neel Syndrome and IGM Neuropathy  M Minnema  4:00 PM
Novel Agents and Approaches  S Treon  4:15 PM
     
Keynote Plenary Lectures    
Immune dysfunction in myeloma pathogenesis Q Yi   (Introduction by
N Munshi)
 4:30 PM
Do degrons represent the next therapeutic advance for MM? N Gray  (Introduction by
K Anderson)
 4:45 PM
Jan Gosta Waldenstrom Award Plenary Lecture
   Towards the Cure of Amyloid Disease
G Merlini (Laudation by
J San Miguel)
5:00 - 5:45 PM
     
Day Adjournment   5:45 PM
     

Closing Ceremonies and Award Presentations
at the Boston Museum of Fine Arts - 7:30 PM

Important Information for Speakers and Presenters 

Parallel Session - Hynes Ballroom

Saturday, September 14, 2019

     
 

Parallel Session - Hynes Ballroom

     
Other Plasma Cell Disorders and Amyloidosis    
Session Chairs V Sanchorawala/E Laane  
AB813: Progression risk stratification of Asymptomatic Waldenstrom Macroglobulinemia  R Sklavenitis-Pistofidis 10:00 AM
AB880: Impact of Chromosome 6q Deletions in Multiple Myeloma and Waldenstrom's Macroglobulinemia by Next Generation RNA Sequencing  ML Guerrera 10:15 AM
AB581: Multicenter prospective phase II study of venetoclax in patients with previously treated Waldenstrom macroglobulinemia  J Castillo 10:30 AM
AB543: A Prospective Phase II of Daratumumab in Previously Treated Systemic Light-Chain (AL) Amyloidosis: Updated Results  M Roussel 10:45 AM
AB559: A Prospective Phase II Trial of Lenalidomide and Dexamethasone in POEMS Syndrome  A Jaccard 11:00 AM
     
Multiple Myeloma MRD Assessment    
Session Chairs  B Paiva/S Holstein  
AB811: Detection and Prevalence of Monoclonal Gammopathy of Undetermined Significance: A study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement  S Dasari 11:15 AM
AB842: Sequential minimal residual disease (MRD) monitoring: results from the UK Myeloma XI trial  R De Tute 11:30 AM
AB512: Stem Cell Mobilization and Autograft Purity with Novel Induction Regimens in Multiple Myeloma  S Bal 11:45 AM
AB172: Prognostic implications of MRD assessment in multiple myeloma patients: comparison of Next-Generation Sequencing and Next-Generation Flow  A Medina 12:00 PM
AB409: Dynamic monitoring of minimal residual disease reveals its superior prognostic significance in multiple myeloma  F Jin 12:15 PM
     

Poster Session II, Lunch and EXhibiTIONS 12:30 - 2:00 PM

     
Multiple Myeloma Novel Drug Targets    
Session Chairs D Chauhan/E Ocio  
AB871: CRISPR studies identify genes preferentially essential for myeloma cells vs. other neoplasias: implications for future therapies selective against MM  R Shirasaki 2:00 PM
AB869: Gain-of-function studies with CRISPR-based transcriptional activation at endogenous genomic loci reveals genes with critical roles for myeloma cells  H Tang 2:15 PM
AB702: Multiple myeloma with amplification of chromosome 1q is highly sensitive to MCL-1 targeting  A Slomp 2:30 PM
AB812: Founding precision therapy for 1q-amplified multiple myeloma  R Sklavenitis-Pistofidis 2:45 PM
AB247: Synthetic lethality in multiple myeloma harboring double oncogenic hits of 17p13(del) and 1q21(amp)  PJ Teoh 3:00 PM
AB426: APOBEC3B is induced by activation of DNA damage pathway and regulates the survival and treatment response in myeloma  L Xing 3:15 PM
     
Multiple Myeloma Novel Agents    
Session Chairs T Steinbrunner/ C Mitsiades  
AB217: A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone (wKRd) in patients (pts) with newly diagnosed multiple myeloma (NDMM)  M Alsina 3:30 PM
AB198: A Phase 1b/2a Study of the CELMoD Iberdomide (CC-220) in Combination With Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma  S Lonial 3:45 PM
AB260: A Phase 1, First-in-Human Study of AMG 176, a Selective MCL-1 Inhibitor, in Patients With Relapsed or Refractory Multiple Myeloma  A Spencer 4:00 PM
AB169: AMG 701, a half-life extended anti-BCMA BiTEĀ®, potently induces T cell-redirected lysis of human multiple myeloma cells and can be combined with IMiDs to overcome the immunosuppressive bone marrow microenvironment  SF Cho  4:15 PM
AB657: CT053, Anti-BCMA CAR T-cell therapy for Relapsed/Refractory Multiple Myeloma: Proof of Concept Results from a Phase I Study  S Hao 4:30 PM
AB353: Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)  D White 4:45 PM
     
Ballroom Sessions Conclude   5:00 PM
     

 Jan Gosta Waldenstrom Award Plenary Lecture - Veterans Auditorium - 5:15 PM

     

 CLOSING CEREMONIES AND AWARD PRESENTATIONS AT THE BOSTON MUSEUM OF FINE ARTS - 7:30 PM

Important Information for Speakers and Presenters 

Parallel Session - Bone Disease - Room 210

Multiple Myeloma Bone Disease - Room 210

     
Multiple Myeloma Bone Disease    
Session Chairs N Raje/E Terpos  
AB142: Fracture Risk Assessment in Patients with Monoclonal Gammopathy of Undetermined Significance: Value of Bone Mineral Density and Trabecular Bone Score  J Sfeir  10:00 AM
AB828: Fractures and Survival in Multiple Myeloma: Results from a Population-Based Study  S Thorsteinsdottir  10:15 AM
AB724: Bone marrow MRI versus 18F-FDG-PET/CT for detecting multiple myeloma lesions: diagnostic performance and clinical relevance  F Lecouvet  10:30 AM
AB337: CXCR4 positron emission tomography for the detection of bone disease in newly diagnosed myeloma  N Weber  10:45 AM
AB430: Prospective evaluation of a quantitative MRI biomarker to assess treatment response for patients with multiple myeloma  L Yang  11:00 AM
AB378: Glutamine addiction of myeloma cells shapes the metabolic features of the bone microenvironment and impairs osteoblast differentiation  D Toscani 11:15 AM
AB251: Transcriptional profiling of cortical bone after mechanical loading in the MOPC315.BM myeloma bone disease model  F Ziouti 11:30 AM
     

PoSter Session II, Lunch and EXhibiTIONS 12:30 -2:00 PM

     

 CLOSING CEREMONIES AND AWARD PRESENTATIONS AT THE BOSTON MUSEUM OF FINE ARTS - 7:30 PM

Important Information for Speakers and Presenters